Skip to main content
. 2014 Aug 8;18(3):385–394. doi: 10.1007/s11102-014-0585-6

Fig. 3.

Fig. 3

Median a GH and b IGF-1 levels during treatment. The total numbers of patients with evaluable measurements for GH and IGF-1 are shown beneath each graph. Oct octreotide LAR; Pas pasireotide LAR